---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-038802"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:12:03.328874+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STRATA Skin Sciences Q2 revenue $8.3M, net loss $3.1M; FY guidance cut to $35-38M

## Summary
- Q2 revenue $8.3M vs $9.1M YoY; equipment revenue down to $2.8M from $3.5M due to $1.5M one-time China sale last year.
- Net loss $3.1M ($0.09 loss per share) vs $1.9M ($0.05 loss) YoY; adjusted EBITDA loss of $95K vs positive $207K.
- FY 2023 guidance revised to $35-38M from prior; cites slowdown in capex and macro factors impacting equipment sales.
- Secured up to $12M financing with MidCap Financial; cash balance $10.4M; includes refinancing and $7M new tranche.
- 73 TheraClear X devices placed; initiated acne clinical study; JCAD publication released.

## SEC filing metadata
- accession: 0001140361-23-038802
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/0001140361-23-038802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/brhc20057162_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-038802
- JSON: https://secwatch.observer/filing/0001140361-23-038802.json
- Plain text: https://secwatch.observer/filing/0001140361-23-038802.txt

## Key facts
- Earnings Releases
  STRATA Skin Sciences, Inc. reported second quarter ended June 30, 2023 results: revenue $8.3 million, net income $3.1 million, or a loss of $0.09 per basic and diluted common share, EPS $0.09 loss per basic and diluted common share. Guidance lowered.
  - Period: second quarter ended June 30, 2023
  - Revenue: $8.3 million
  - Net income: $3.1 million, or a loss of $0.09 per basic and diluted common share
  - EPS: $0.09 loss per basic and diluted common share
  - Guidance: lowered
  - Result: reported results
  source text: today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights: ● Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022. ● Secured up to an additional $12 million financing with MidCap Financial. ● Placed 73 TheraClear ® X devices as of June
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/0001140361-23-038802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.